Cetrelimab not checked
Johnson & Johnson (Janssen) · JNJ-63723283
FollowEvery change as it happens, and a Monday email
Trials
13 active
18 in total · 12 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants will receive cetrelimab 240 mg IV every 2 weeks.”In the company’s words, NCT03431350 on ClinicalTrials.gov
- Tested for
- Neoplasms (3 trials), Urinary Bladder Neoplasms (2 trials), Carcinoma, Non-Small-Cell Lung (2 trials), Bladder Cancer, Prostatic Neoplasms, Castration-Resistant, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
- Main trialPhase 3
- “The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.”In the company’s words, NCT04658862 on ClinicalTrials.gov
- Other names
- JNJ-63723283
Other drugs for Neoplasms
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up7
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 14 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 12 Jan 2028Phase 1 trial completes · ClinicalTrials.gov
- 8 Nov 2028Phase 1 trial completes · ClinicalTrials.gov
- 18 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Dec 2026 | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | |
| Phase 3Active, not recruiting | 18 Sep 2029 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) | |
| Phase 2Active, not recruiting | 31 Aug 2021 | A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | |
| Phase 2Active, not recruiting | 3 Jul 2025 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | |
| Phase 1/2Active, not recruiting | 30 Sep 2022 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | |
| Phase 1/2Active, not recruiting | 17 Nov 2023 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers | |
| Phase 1/2Active, not recruiting | 31 Jan 2027 | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer | |
| Phase 1Active, not recruiting | 14 Apr 2027 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | |
| Phase 1Recruiting | 31 Aug 2027 | A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | |
| Phase 1Recruiting | 12 Jan 2028 | A Study of JNJ-1761981 in Participants With Solid Tumors | |
| Phase 1Recruiting | 8 Nov 2028 | A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | |
| Phase 2/3Completed | 24 Oct 2018 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 2Completed | 4 Feb 2025 | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder | |
| Phase 1Completed | 11 Nov 2021 | A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1Completed | 4 Jul 2022 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers | |
| Phase 1Completed | 9 May 2023 | A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection | |
| Phase 2Authorised | not given | A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN) | |
| Phase 1/2Authorised | not given | CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026